Aranidipine
Antihypertensive drug of the calcium channel blocker class
- none
- In general: ℞ (Prescription only)
- O5-methyl O3-(2-oxopropyl)
- 86780-90-7
Y
- 2225
- 2139 Y
- 4Y7UR6X2PO
- D01562 Y
- ChEMBL2104030
- DTXSID9048649
- Interactive image
- CC1=C(C(C(=C(N1)C)C(=O)OCC(=O)C)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC
InChI
- InChI=1S/C19H20N2O7/c1-10(22)9-28-19(24)16-12(3)20-11(2)15(18(23)27-4)17(16)13-7-5-6-8-14(13)21(25)26/h5-8,17,20H,9H2,1-4H3Y
- Key:NCUCGYYHUFIYNU-UHFFFAOYSA-NY
Aranidipine (INN, trade name Sapresta) is a calcium channel blocker. It is a dihydropyridine derivative with two active metabolites (M-1α and M-1β). It was developed by Maruko Seiyaku and has the formula methyl 2-oxopropyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate. Its main use is as a hypotensive, reducing blood pressure.[1][2]
References
- v
- t
- e
Ion channel modulators
| VGKCsTooltip Voltage-gated potassium channels |
| ||||
|---|---|---|---|---|---|
| IRKsTooltip Inwardly rectifying potassium channel |
| ||||
| KCaTooltip Calcium-activated potassium channel |
| ||||
| K2PsTooltip Tandem pore domain potassium channel |
|
| VGSCsTooltip Voltage-gated sodium channels |
| ||||
|---|---|---|---|---|---|
| ENaCTooltip Epithelial sodium channel |
| ||||
| ASICsTooltip Acid-sensing ion channel |
|
| CaCCsTooltip Calcium-activated chloride channel |
| ||||
|---|---|---|---|---|---|
| CFTRTooltip Cystic fibrosis transmembrane conductance regulator |
| ||||
| Unsorted |
|
| TRPsTooltip Transient receptor potential channels |
|
|---|---|
| LGICsTooltip Ligand gated ion channels |
|
See also: Receptor/signaling modulators • Transient receptor potential channel modulators
 | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
